B-intervention	0	9	Docetaxel
O	10	12	vs
B-control	13	14	5
I-control	14	15	-
I-control	15	27	fluorouracil
I-control	28	32	plus
I-control	33	44	vinorelbine
O	45	47	in
O	48	58	metastatic
O	59	65	breast
O	66	72	cancer
O	73	78	after
O	79	92	anthracycline
O	93	100	therapy
O	101	108	failure
O	108	109	.

O	110	114	This
O	115	126	multicentre
O	126	127	,
O	128	138	randomised
O	139	144	phase
O	145	148	III
O	149	154	study
O	155	163	compared
O	164	173	docetaxel
O	174	178	with
O	179	180	5
O	180	181	-
O	181	193	fluorouracil
O	193	194	+
O	194	205	vinorelbine
O	206	208	in
O	209	217	patients
O	218	222	with
O	223	233	metastatic
O	234	240	breast
O	241	247	cancer
O	248	253	after
O	254	261	failure
O	262	264	of
O	265	268	neo
O	268	269	/
O	269	277	adjuvant
O	278	280	or
O	281	284	one
O	285	289	line
O	290	292	of
O	293	303	palliative
O	304	317	anthracycline
O	317	318	-
O	318	323	based
O	324	336	chemotherapy
O	336	337	.

B-total-participants	338	341	One
I-total-participants	342	349	hundred
I-total-participants	350	353	and
I-total-participants	354	361	seventy
I-total-participants	361	362	-
I-total-participants	362	365	six
B-eligibility	366	376	metastatic
I-eligibility	377	383	breast
I-eligibility	384	390	cancer
I-eligibility	391	399	patients
O	400	404	were
O	405	415	randomised
O	416	418	to
O	419	426	receive
O	427	436	docetaxel
O	437	438	(
O	438	441	100
O	442	444	mg
O	445	446	m
O	446	447	(
O	447	448	-
O	448	449	2
O	449	450	)
O	450	451	)
O	452	457	every
O	458	459	3
O	460	465	weeks
O	466	468	or
O	469	470	5
O	470	471	-
O	471	483	fluorouracil
O	483	484	+
O	484	495	vinorelbine
O	495	496	:
O	497	498	5
O	498	499	-
O	499	511	fluorouracil
O	512	513	(
O	513	516	750
O	517	519	mg
O	520	521	m
O	521	522	(
O	522	523	-
O	523	524	2
O	524	525	)
O	526	529	per
O	530	533	day
O	534	544	continuous
O	545	553	infusion
O	553	554	)
O	555	557	D1
O	557	558	-
O	558	559	5
O	560	564	plus
O	565	576	vinorelbine
O	577	578	(
O	578	580	25
O	581	583	mg
O	584	585	m
O	585	586	(
O	586	587	-
O	587	588	2
O	588	589	)
O	589	590	)
O	591	593	D1
O	594	597	and
O	598	600	D5
O	601	603	of
O	604	608	each
O	609	610	3
O	610	611	-
O	611	615	week
O	616	621	cycle
O	621	622	.

B-intervention-participants	623	629	Eighty
I-intervention-participants	629	630	-
I-intervention-participants	630	633	six
O	634	642	patients
O	643	651	received
O	652	655	516
O	656	662	cycles
O	663	665	of
O	666	675	docetaxel
O	675	676	;
B-control-participants	677	679	90
O	680	688	patients
O	689	697	received
O	698	701	476
O	702	708	cycles
O	709	711	of
O	712	713	5
O	713	714	-
O	714	726	fluorouracil
O	726	727	+
O	727	738	vinorelbine
O	738	739	.

B-outcome	740	746	Median
I-outcome	747	751	time
I-outcome	752	754	to
I-outcome	755	766	progression
O	767	768	(
B-iv-cont-median	768	769	6
I-iv-cont-median	769	770	.
I-iv-cont-median	770	771	5
O	772	774	vs
B-cv-cont-median	775	776	5
I-cv-cont-median	776	777	.
I-cv-cont-median	777	778	1
I-cv-cont-median	779	785	months
O	785	786	)
O	787	790	and
B-outcome	791	798	overall
I-outcome	799	807	survival
O	808	809	(
B-iv-cont-median	809	811	16
I-iv-cont-median	811	812	.
I-iv-cont-median	812	813	0
O	814	816	vs
B-cv-cont-median	817	819	15
I-cv-cont-median	819	820	.
I-cv-cont-median	820	821	0
I-cv-cont-median	822	828	months
O	828	829	)
O	830	833	did
O	834	837	not
O	838	844	differ
O	845	858	significantly
O	859	866	between
O	867	870	the
O	871	880	docetaxel
O	881	884	and
O	885	886	5
O	886	887	-
O	887	899	fluorouracil
O	899	900	+
O	900	911	vinorelbine
O	912	916	arms
O	916	917	,
O	918	930	respectively
O	930	931	.

B-iv-bin-abs	932	935	Six
O	936	937	(
B-iv-bin-percent	937	938	7
I-iv-bin-percent	938	939	%
O	939	940	)
B-outcome	941	949	complete
I-outcome	950	959	responses
O	960	963	and
B-iv-bin-abs	964	966	31
O	967	968	(
B-iv-bin-percent	968	970	36
I-iv-bin-percent	970	971	%
O	971	972	)
B-outcome	973	980	partial
I-outcome	981	990	responses
O	991	999	occurred
O	1000	1004	with
O	1005	1014	docetaxel
O	1015	1016	(
B-outcome	1016	1023	overall
I-outcome	1024	1032	response
I-outcome	1033	1037	rate
B-iv-bin-percent	1038	1040	43
I-iv-bin-percent	1040	1041	%
O	1041	1042	,
O	1043	1045	95
O	1045	1046	%
O	1047	1057	confidence
O	1058	1066	interval
O	1066	1067	:
O	1068	1070	32
O	1070	1071	-
O	1071	1073	53
O	1073	1074	%
O	1074	1075	)
O	1075	1076	,
O	1077	1082	while
B-cv-bin-abs	1083	1084	4
O	1085	1086	(
B-cv-bin-percent	1086	1087	4
I-cv-bin-percent	1087	1088	.
I-cv-bin-percent	1088	1089	4
I-cv-bin-percent	1089	1090	%
O	1090	1091	)
B-outcome	1092	1100	complete
I-outcome	1101	1110	responses
O	1111	1114	and
B-cv-bin-abs	1115	1117	31
O	1118	1119	(
B-cv-bin-percent	1119	1121	34
I-cv-bin-percent	1121	1122	.
I-cv-bin-percent	1122	1123	4
I-cv-bin-percent	1123	1124	%
O	1124	1125	)
B-outcome	1126	1133	partial
I-outcome	1134	1143	responses
O	1144	1152	occurred
O	1153	1157	with
O	1158	1159	5
O	1159	1160	-
O	1160	1172	fluorouracil
O	1172	1173	+
O	1173	1184	vinorelbine
O	1185	1186	(
B-outcome	1186	1193	overall
I-outcome	1194	1202	response
I-outcome	1203	1207	rate
B-cv-bin-percent	1208	1210	38
I-cv-bin-percent	1210	1211	.
I-cv-bin-percent	1211	1212	8
I-cv-bin-percent	1212	1213	%
O	1213	1214	,
O	1215	1217	95
O	1217	1218	%
O	1219	1229	confidence
O	1230	1238	interval
O	1238	1239	:
O	1240	1242	29
O	1242	1243	-
O	1243	1245	49
O	1245	1246	%
O	1246	1247	)
O	1247	1248	.

O	1249	1253	Main
B-outcome	1254	1259	grade
I-outcome	1260	1261	3
I-outcome	1261	1262	-
I-outcome	1262	1263	4
I-outcome	1264	1274	toxicities
O	1275	1279	were
O	1280	1281	(
O	1281	1290	docetaxel
O	1291	1293	vs
O	1294	1295	5
O	1295	1296	-
O	1296	1308	fluorouracil
O	1308	1309	+
O	1309	1320	vinorelbine
O	1320	1321	)
O	1321	1322	:
B-outcome	1323	1334	neutropenia
B-iv-bin-percent	1335	1337	82
I-iv-bin-percent	1337	1338	%
O	1339	1341	vs
B-cv-bin-percent	1342	1344	67
I-cv-bin-percent	1344	1345	%
O	1345	1346	;
B-outcome	1347	1357	stomatitis
B-iv-bin-percent	1358	1359	5
I-iv-bin-percent	1359	1360	%
O	1361	1363	vs
B-cv-bin-percent	1364	1366	40
I-cv-bin-percent	1366	1367	%
O	1367	1368	;
B-outcome	1369	1376	febrile
I-outcome	1377	1388	neutropenia
B-iv-bin-percent	1389	1391	13
I-iv-bin-percent	1391	1392	%
O	1393	1395	vs
B-cv-bin-percent	1396	1398	22
I-cv-bin-percent	1398	1399	%
O	1399	1400	;
O	1401	1404	and
B-outcome	1405	1414	infection
B-iv-bin-percent	1415	1416	2
I-iv-bin-percent	1416	1417	%
O	1418	1420	vs
B-cv-bin-percent	1421	1422	7
I-cv-bin-percent	1422	1423	%
O	1423	1424	.

O	1425	1430	There
O	1431	1434	was
B-iv-bin-abs	1435	1438	one
O	1439	1447	possible
B-outcome	1448	1457	treatment
I-outcome	1457	1458	-
I-outcome	1458	1465	related
I-outcome	1466	1471	death
O	1472	1474	in
O	1475	1478	the
O	1479	1488	docetaxel
O	1489	1492	arm
O	1493	1496	and
B-cv-bin-abs	1497	1501	five
O	1502	1506	with
O	1507	1508	5
O	1508	1509	-
O	1509	1521	fluorouracil
O	1521	1522	+
O	1522	1533	vinorelbine
O	1533	1534	.

O	1535	1537	In
O	1538	1551	anthracycline
O	1551	1552	-
O	1552	1562	pretreated
O	1563	1573	metastatic
O	1574	1580	breast
O	1581	1587	cancer
O	1588	1596	patients
O	1596	1597	,
O	1598	1607	docetaxel
O	1608	1614	showed
O	1615	1625	comparable
O	1626	1634	efficacy
O	1635	1637	to
O	1638	1639	5
O	1639	1640	-
O	1640	1652	fluorouracil
O	1652	1653	+
O	1653	1664	vinorelbine
O	1664	1665	,
O	1666	1669	but
O	1670	1673	was
O	1674	1678	less
O	1679	1684	toxic
O	1684	1685	.
